Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
February 26, 2018

Immuno-Oncology clinical trials increased at 17% average yearly growth

GlobalData has reviewed global clinical trials in immuno-oncology (IO) for 2008–2017: they increased at a 17% Compound Annual Growth Rate (CAGR) over the 10-year period.

GlobalData has reviewed global clinical trials in immuno-oncology (IO) for 2008–2017: they increased at a 17% Compound Annual Growth Rate (CAGR) over the 10-year period.

For the purposes of this analysis, a small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively. Overall, Phase II trials outnumbered all other trials by contributing between 52% and 62% across the period, or 57% on average.

The share of Phase I trials remained at around 31% across the 10-year period, as shown in Figure 1.

Phase III trials’ contribution ranged between 7% and 12%, or 9% on average, whereas Phase IV trials’ share remained flat at approximately 3%.

This shows the fast pace IO features with regard to the development of new drugs. It also highlights the relatively early stage the field is in, considering that 88% of the trials are in Phase II or below.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU